Vir Biotechnology, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company with common stock traded under VIR. Its SEC disclosures cover operating and financial results, cash and investment updates, clinical and regulatory communications, material agreements, and capital-structure actions related to common stock issuances and collaborations.
The company’s proxy and current reports also describe board and executive governance, compensation matters, shareholder voting items, leadership changes, and registered security information. For Vir’s business model, the filings connect pipeline spending, development-stage risk factors, collaboration economics, intellectual property matters, and financing activity to programs in chronic hepatitis delta, PRO-XTEN® T-cell engagers, and preclinical infectious disease and oncology research.
Vir Biotechnology, Inc. reported that its Phase 3 ECLIPSE 1 trial met its primary and key secondary endpoints for elebsiran plus tobevibart in adults with chronic hepatitis delta. The primary endpoint response was 44% at Week 48, defined as undetectable HDV RNA plus ALT normalization, versus 0% in the delayed-treatment group at Week 12 (p<0.0001). The key secondary undetectable-virus response was 79% at Week 48 versus 0% in the delayed-treatment group. ECLIPSE 1 randomized 124 patients 2:1. One Grade 3 treatment-related neutrophil-count decrease resolved in 15 days; there were no treatment interruptions or discontinuations.
In Phase 2 SOLSTICE, 28 of 28 patients completing 96 weeks of combination therapy had undetectable viremia, and 89% (24 of 27) with paired liver-stiffness measures had improved or stable readings. In an exploratory treatment-discontinuation analysis, all 10 patients achieved SVR12; among those with later follow-up, 7 achieved SVR24 and 1 achieved SVR48. These first-10-patient data are preliminary and interim, follow-up is ongoing and incomplete, and the company said they do not establish a sustained treatment-free response or cure. The Phase 2 regimen had no study drug-related discontinuations or serious adverse events.
Vir Biotechnology, Inc. (VIR)'s Schedule 13D amendment reports cash sales by two affiliated funds: ARCH Venture Fund IX, L.P. sold 347,819 shares, and ARCH Venture Fund IX Overage, L.P. sold 448,356 shares, from November 3 through November 5, 2026.
The amendment lists Fund IX as record owner of 5,055,689 shares and Overage as record holder of 6,842,299 shares. Reporting persons' beneficial-ownership percentages range from 6.9% to 7.3%, based on 171,270,773 shares outstanding as of October 28, 2026. It states that affiliated entities with overlapping general partners and managing directors may share voting and disposition power over the record shares.
Vir Biotechnology, Inc. (VIR) reported a nine-month net loss of $141.9 million, compared with $395.1 million in 2025, while revenue was $238.7 million versus $4.5 million. Revenue included $239.3 million recognized from the Astellas collaboration. Net cash used in operating activities was $115.1 million, compared with $365.9 million.
As of September 30, 2026, VIR had approximately $901.3 million in cash, cash equivalents and investments, which it said would fund operations for at least 12 months from the statements’ issuance date. The Astellas agreement covers joint development of VIR-5500, with up to $1.39 billion in future milestones and tiered, double-digit royalties on ex-U.S. sales; U.S. profits and losses would be shared equally if the product is approved.
On October 9, VIR and Gilead entered a collaboration to develop three preclinical candidates. VIR received $90.0 million in cash in October, including a $65.0 million upfront payment and a $25.0 million equity investment, and is eligible for up to $45.0 million in near-term preclinical milestones and up to $1.74 billion in further milestones, plus tiered royalties.
Vir Biotechnology, Inc. reported a third-quarter 2026 net loss of $96.3 million, compared with $163.1 million a year earlier, or $0.57 per share versus $1.17. Research and development expense was $80.0 million versus $151.5 million, primarily reflecting a non-recurring $75.0 million milestone expense in 2025 and collaboration cost recoveries in 2026; higher manufacturing costs partly offset the decrease.
As of September 30, 2026, cash, cash equivalents and investments were approximately $901.3 million, excluding $90 million in upfront consideration from Gilead, and had decreased by $106.5 million during the quarter. Vir expects its cash, cash equivalents and investments to fund operations into the second half of 2028. It received $90 million in consideration under its Gilead collaboration: $65 million upfront and a $25 million equity investment at a 30% premium. Vir is eligible for up to $45 million in near-term preclinical milestones and has potential to receive up to $1.74 billion in development, regulatory and commercial milestones, plus tiered royalties. ECLIPSE 1 topline data are expected in the fourth quarter of 2026; ECLIPSE 2 and 3 topline data are expected in the first quarter of 2027. VIR-5500 received FDA Fast Track designation, achieved proof of concept, and is expected to advance to multiple pivotal trials beginning in 2027.
Vir Biotechnology, Inc. EVP, General Counsel and Corporate Secretary Vanina de Verneuil reported two sales of common stock: 1,343 shares at $11.334 per share on November 2, 2026, and 2,407 shares at $11.10 per share on November 3, 2026. Both sales were made under a Rule 10b5-1 trading plan adopted May 26, 2026. The November 2 sale was automatic and mandatory to satisfy the issuer's tax-withholding obligations tied to restricted stock unit vesting, and was not discretionary.
Vir Biotechnology, Inc. officer Vanina A. Huard de Verneuil reported a proposed sale of 2,407 common shares, with an approximate sale date of November 3, 2026, and an aggregate market value of $26,717.70. The listed broker is Fidelity Brokerage Services LLC. Huard de Verneuil also reported 1,343 common shares sold on November 2, 2026, for $15,221.96.
Vir Biotechnology, Inc. officer Vanina Huard de Verneuil reported a proposed sale of 1,343 common shares, with an aggregate market value of $15,221.96, for November 2, 2026. Fidelity Brokerage Services LLC is listed as broker and NASDAQ as the exchange. The notice says the sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution.
Vir Biotechnology, Inc. director Suzanne Louise Topalian was granted 8,000 and 4,731 restricted stock units (RSUs), plus options covering 16,000 and 9,462 shares, on October 27, 2026. Both option awards have an $11.57 exercise price and expire October 26, 2036.
Vir Biotechnology, Inc. director Suzanne Louise Topalian’s October 27, 2026, ownership entry lists 0 shares of common stock held directly.
Vir Biotechnology, Inc. (VIR) expanded its board from eight to nine members and appointed Suzanne Topalian, M.D., as a Class III director, effective October 27, 2026. Topalian will serve until the company’s 2028 annual meeting of stockholders and join the Science and Technology Committee. The company said she was not selected under an arrangement or understanding with any person and that no related-party transactions with her were subject to disclosure. In addition to the indemnification provided to directors under its bylaws, Vir entered into its standard form of indemnity agreement with Topalian.